Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Canakinumab vs Colchicine: they're closely matched on evidence (4 vs 3/10); they're alternatives for inflammation-related symptoms — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Canakinumab and Colchicine are closely matched across evidence, studies, and safety.
Verdict
Too few graded studies
Top outcomes
Verdict
Too few graded studies
Top outcomes
Shared outcomes (2)
Outcomes where both Canakinumab and Colchicine have evidence — compare verdict strength side-by-side.
A prescription biologic, not self-administered for longevity. Approved CAPS dosing is 150 mg subcutaneously every 8 weeks (weight-adjusted in children). The CANTOS cardiovascular regimen was 150 mg subcutaneously every 3 months. There is NO established off-label longevity protocol, and cost is prohibitive.
Any time of day
Subcutaneous injection (clinician-administered)
Off-label cardiovascular/geroprotective use is low-dose: 0.5 mg once daily (the regimen in the cited LoDoCo and COLCOT trials) under a clinician. Acute gout uses higher short-course dosing. Not an approved longevity regimen; mind the drug interactions.
Any time of day
Low-dose oral tablet (0.5 mg/day)
Months to years
Weeks
Trial endpoints
Throughout use
Months to years
Weeks
Trial endpoints
Throughout use
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.
The New England journal of medicine (2017) · Rct · n=10061
CANTOS: randomized, double-blind, placebo-controlled trial in ~10,000 post-MI patients with elevated hsCRP
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial.
Lancet (2017) · Rct
Exploratory analysis of the CANTOS cohort — incident and fatal lung cancer as pre-specified secondary endpoints
Canakinumab in combination with docetaxel compared with docetaxel alone for the treatment of advanced non-small cell lung cancer following platinum-based doublet chemotherapy and immunotherapy (CANOPY-2): A multicenter, randomized, double-blind, phase 3 trial.
Lung cancer (Amsterdam, Netherlands) (2024) · Rct · n=237
CANOPY-2: phase 3 randomized, double-blind trial in advanced non-small-cell lung cancer
Low-dose colchicine for secondary prevention of cardiovascular disease.
Journal of the American College of Cardiology (2013) · Rct · n=532
LoDoCo randomized trial of low-dose colchicine in stable coronary disease
Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction.
The New England journal of medicine (2019) · Rct
COLCOT randomized, placebo-controlled trial of colchicine 0.5 mg/day after MI
Colchicine for Secondary Prevention of Coronary Artery Disease: A Meta-Analysis of Randomised Controlled Trials.
Heart, lung & circulation (2022) · Meta analysis
Meta-analysis of colchicine trials for secondary cardiovascular prevention
Both Canakinumab and Colchicine are closely matched — the best choice depends on your specific health goals.
Both Canakinumab and Colchicine score equally (80) for inflammation-related symptoms.
No known interactions between Canakinumab and Colchicine have been documented in our database. However, always consult a healthcare provider before combining supplements.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.